NCT06622967 is a NA clinical trial of CadAI-B in Breast Neoplasm, sponsored by JeeYeon Lee.

Who is sponsoring NCT06622967?

NCT06622967 is sponsored by JeeYeon Lee.

What drugs are being tested in NCT06622967?

Interventions in NCT06622967: CadAI-B.

What condition does NCT06622967 study?

NCT06622967 studies Breast Neoplasm, Female.

Is NCT06622967 still recruiting?

NCT06622967 is currently active, enrolled. Last updated 2 October 2024.

Last reviewed 2024-10-02 · How we verify

NCT06622967

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

KNUCH CadAI-B-1(KCB-1)

Active, enrolled NA Last updated 2 October 2024

What this trial tests

NA trial testing CadAI-B in Breast Neoplasm in 100 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

15 September 2024

Primary endpoint
31 October 2024

31 December 2024

Quick facts

Lead sponsor	JeeYeon Lee
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	100
Start date	15 September 2024
Primary completion	31 October 2024
Estimated completion	31 December 2024
Sites	1 location across South Korea

Drugs / interventions tested

CadAI-B

Conditions studied

Breast Neoplasm — all drugs for Breast Neoplasm →
Female — all drugs for Female →

Sponsor

JeeYeon Lee

Who can join

20 and older, female only, with Breast Neoplasm or Female. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The CadAI-B (Computer Aided Design Artificial Intelligence-Breast) system is a real-time AI diagnostic tool for breast ultrasound. It integrates with ultrasound devices to detect suspicious lesions, providing size, BI-RADS, and malignancy probability. After installation and user training, the system displays real-time breast conditions and automatically analyzes lesions when a freeze frame is set, showing results in seconds. This study will assess CadAI-B\'s accuracy and reliability by comparing its findings with biopsy results.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Breast Neoplasm

Currently open trials in the same condition.

NCT07054723 — Surviving Daily Life · recruiting
NCT06839001 — CRYoablation for Small Tumors As Local Treatment - SIX Trial · Phase 3 · recruiting
NCT06672302 — A Prospective Study to Develop and Clinically Validate an in Vitro Diagnostic Medical Device That Uses Blood to Classify · recruiting
NCT06255808 — Development of Assist Tool for Breast Examination Using the Principle of Ultrasonic Sensor · active not recruiting
NCT05505643 — Cryoablation vs Lumpectomy in T1 Breast Cancers · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06622967 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by JeeYeon Lee
Last refreshed: 2 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06622967.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing